EMBARK vs MDMA-Assisted Therapy

A side-by-side comparison of recorded mechanisms, evidence review status, related condition topics, and philosophical roots.

By Expert review not yet recorded Updated

At a glance

Source checks, condition-specific assessments and expert review are separate steps. Each assessment applies only to its stated population and use. Topic links do not establish comparative effectiveness.

EMBARK

Tradition
Psychedelic
Founder
Brennan / Belser (2022)
Review status
Assessment not yet completed
Focus
Integration + Processing
Format
Individual (dyadic facilitation team)
Duration
Variable (structured phases: preparation, medicine sessions, integration)

MDMA-Assisted Therapy

Tradition
Psychedelic
Founder
MAPS / Mithoefer (2021)
Review status
4 source checks available
Official sources
Guidelines and official sources (4)

3 clinical guideline checks · 1 regulatory source check

Read the recommendation and its scope. A source may discuss an approach without recommending it.

  • NDA 215455: midomafetamine complete response letter

    US Food and Drug Administration · 2024-08-08; Reference ID 5427030 · Regulatory source · Complete response issues 1–3, pages 1–4; additional comments pages 5–6

    Not a treatment recommendation

    The letter verifies the 2024 nonapproval decision and identifies safety reporting, durability and bias concerns. Psychotherapy-contribution questions appear separately as additional comments.

    Scope: Midomafetamine application NDA 215455 for PTSD

    Source checked

  • Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder

    VA/DoD · 2023 · Clinical guideline · Recommendation 23; Table 6, p.37

    Insufficient evidence for or against

    VA/DoD finds insufficient evidence for or against MDMA-assisted psychotherapy. The guideline’s evidence cutoff precedes later trials and regulatory decisions.

    Scope: MDMA-assisted psychotherapy for adults with PTSD; evidence reviewed through May 2022.

    Source checked

  • Management of Major Depressive Disorder

    VA/DoD · Version 4.0, February 2022; evidence through January 2021 · Clinical guideline · Recommendation 35; pp.26,67–68

    Recommendation against the stated use

    VA/DoD strongly recommends against MDMA for MDD outside research. This 2022 guideline used evidence through January 2021; it does not assess later trials or every diagnosis.

    Scope: MDMA for MDD outside research settings.

    Source checked

  • Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults

    American Psychological Association · Approved February 2025; 2025 update · Clinical guideline · Psychedelic interventions, printed p.14 (PDF p.18)

    Insufficient evidence for or against

    APA finds insufficient evidence for or against this intervention in the reviewed comparisons.

    Scope: Adults with PTSD; MDMA-assisted psychotherapy versus the inactive or low-dose active comparators reviewed.

    Source checked

Focus
Experiential + Processing
Format
Individual (co-therapist)
Duration
Short (3 sessions)

How they work

EMBARK

Core mechanism: Six domains the model holds to be common in psychedelic states organize preparation and integration; four 'care cornerstones' are meant to keep delivery ethical, trauma-informed, and culturally responsive. The structure organizes the therapy rather than explaining how psychedelics work.

Ontology: A whole person whose psychedelic experience activates multiple dimensions simultaneously (existential, somatic, relational, affective-cognitive) requiring a multi-domain therapeutic response rather than a single-mechanism model

MDMA-Assisted Therapy

Core mechanism: MDMA reduces the fear response and increases trust and empathy, making it possible to stay with trauma material inside the therapeutic relationship

Ontology: PTSD maintained by overwhelming fear that prevents therapeutic engagement; MDMA lowers this barrier pharmacologically

Related condition topics

These editorial cross-references organize reading. A shared link does not mean both approaches are effective, recommended, or interchangeable for that condition.

2 shared · 4 EMBARK-only · 0 MDMA-Assisted Therapy-only

Linked to both entries

PTSD & Acute TraumaComplex Trauma / Developmental Trauma

Linked only in the EMBARK entry

Depression & Mood DisordersAnxiety DisordersSubstance Use & AddictionsExistential & Meaning-Making Concerns

What each assumes — and misses

EMBARK

Philosophical roots: Grof (non-ordinary states); James (varieties of religious experience); harm reduction philosophy; CBT, ACT, and psychodynamic traditions integrated

Blind spots: Developed within a pharmaceutical research context (Cybin); limited independent replication; open-source status means variable implementation quality; requires specialized training not yet standardized across programs

Therapeutic voice: You keep coming back to what your body was doing when it started. Let's stay there a while before we go to what it meant.

MDMA-Assisted Therapy

Philosophical roots: Mithoefer (inner healing intelligence); Rogers (organismic wisdom, given conditions); Buber (I-Thou enabled pharmacologically); trauma processing theory

Blind spots: FDA declined approval (2024); methodological concerns about unblinding; not currently legally available outside research

Therapeutic voice: You're safe here. If something difficult comes up, you can move toward it. You don't have to do this alone.

Choosing between them

EMBARK and MDMA-Assisted Therapy both sit within the Psychedelic tradition — they share a worldview about what suffering is and how change happens. Differences are more often about technique and emphasis than about underlying theory.

For deeper coverage: see the full EMBARK and MDMA-Assisted Therapy pages, or use the interactive comparison tool to add more modalities to this comparison.